ASCO in Action

ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.

To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.

March 12, 2024

The Association for Clinical Oncology (ASCO) is closely following cases before the United States Supreme Court that have the potential to significantly impact the delivery of cancer care in the U.S. by reshaping the authority of the federal agencies that regulate health care in the country. The Court is expected to issue rulings in these cases before its current session ends in June 2024.

March 11, 2024

Congress passed a six-part spending bill on March 8, 2024, that funds several government agencies, including the Food and Drug Administration (FDA), through Sept. 30, 2024—the end of the fiscal year.

March 11, 2024

In his last State of the Union address this term, President Joe Biden emphasized critical policy priorities that the Association for Clinical Oncology (ASCO) continues to advocate for on behalf of oncologists, their teams, and the profession.

March 7, 2024

On March 6, 2024, the Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Company) in combination with cisplatin and gemcitabine for first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC).

March 7, 2024

On March 7, 2024, the Food and Drug Administration granted accelerated approval to zanubrutinib (Brukinsa, BeiGene USA, Inc.) with obinutuzumab for relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.

March 7, 2024

The Association for Clinical Oncology (ASCO) is urging President Biden to keep cancer care and research among his top national priorities on the eve of his State of the Union Address.

March 6, 2024

On February 13, 2024, the Food and Drug Administration approved irinotecan liposome (Onivyde, Ipsen Biopharmaceuticals, Inc.) with oxaliplatin, fluorouracil, and leucovorin, for the first-line treatment of metastatic pancreatic adenocarcinoma.

March 1, 2024

On March 1, 2024, the Food and Drug Administration approved amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) with carboplatin and pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test. 

February 29, 2024

Congress passed a continuing resolution (CR) on February 29, 2024, that extends FY 2023 federal funding levels until March 22 for several government agencies, including the National Institutes of Health (NIH) and the National Cancer Institute (NCI).

February 28, 2024

The President's Cancer Panel published a report on February 28 on the National Cancer Plan that includes mention of seven American Society of Clinical Oncology (ASCO) programs that are contributing to the plan.

February 27, 2024

This month, Members of Congress sent letters to Senate leadership urging the Senate to use upcoming government funding legislation to address the Medicare physician payment cuts that took effect on January 1. With the March government funding deadlines coming up, the letter requests that the House and Senate work together to include provisions that provide stability to physician payments. The Association for Clinical Oncology urged House and Senate members to sign the letters and continues to monitor efforts to address Medicare physician cuts. 

 

February 26, 2024

The Federal Trade Commission and the U.S. Department of Health and Human Services issued a joint Request for Information on how group purchasing organizations’ and drug wholesalers’ practices are impacting the generic drug market. The Association for Clinical Oncology encourages stakeholders within the cancer community to comment to give federal agencies the perspective they need from across the myriad settings of cancer care. 

 

February 22, 2024

The American Society of Clinical Oncology (ASCO)’s new policy statement highlights the need for formalized efforts to address health-related social needs and outlines ways to address social determinants of health in cancer care.

February 16, 2024

On February 16, 2024, the Food and Drug Administration approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals LP) with platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (la/mNSCLC) whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. 

February 16, 2024

On February 15, 2024, the Food and Drug Administration granted traditional approval to tepotinib (Tepmetko, EMD Serono, Inc.) for adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations. 

Pages